Research programme: 3-phosphoinositide-dependent kinase-1 inhibitors - Bayer HealthCare PharmaceuticalsAlternative Names: BX-320; BX-517; BX-795; BX-912; PDK1 inhibitors - Bayer HealthCare Pharmaceuticals
Latest Information Update: 23 Mar 2010
At a glance
- Originator Berlex Biosciences
- Mechanism of Action 3 phosphoinositide dependent protein kinase 1 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Solid tumours